BLIS Technologies

BLIS Technologies Limited is reporting revenue growth of 23% and ebitda of $0.5m for the first quarter, ending June 30, 2024.

Revenue for 1Q25 was $3.4m, an increase of $0.6m compared with the same period past year. Ebitda was up $0.5m on the breakeven result from 1Q24.

The biotechnology company commenced business in August 2000 when it acquired, from the University of Otago, rights to Salivaricin B, a substance that acts as a natural antibiotic to control streptococcal throat infections. Since then, it has acquired the university's collection of several thousand BLIS (bacteriocin-like-inhibitory substances) producing organisms collected over 25 years by Professor John Tagg, now a consultant to the company.

Chief executive officer Scott Johnson said the outlook for the FY25 year was double-digit revenue growth on FY24 and an ebitda result similar to last year, noting the result will include a material investment in China regulatory access of $0.5m.

Company Details

Registered Office: Ground Floor, 442 Moray Place, Dunedin 9016

Postal Address: Ground Floor, 442 Moray Place, Dunedin 9016

Telephone: +64-347-41338

Facsimile: n/a

Website: http://www.blis.co.nz/

First Listed: 30/07/2001

Balance Date: 31 March

AGM: 21/07/2022

Directors and Executives

Jorn Andreas

Director

Antony Balfour

Independent Director

Geoff Plunket

Chair

Barry Richardson

Independent Director

Dr Alison Stewart

Independent Director

Brian Watson

Chief Executive Officer

Richard Wingham

Chief Financial Officer

Announcements

Title	Date	Type
Partnership with Chinese Distributor	Fri, Nov 15 2024 02:02 pm	MKTUPDTE
Patent and commercial terms in negotiation	Mon, Oct 14 2024 12:15 pm	MKTUPDTE
BLT – Trading to resume at market open	Tue, Sep 24 2024 08:43 am	HALT
Update on patent issue	Tue, Sep 24 2024 08:30 am	MKTUPDTE
Blis Technologies Ltd (“BLT”) – Trading Halt of Securities	Fri, Sep 20 2024 09:53 am	HALT
Change of registered office	Fri, Sep 06 2024 11:26 am	ADMIN
2024 Annual Shareholder Meeting Results Announcement	Wed, Aug 28 2024 01:55 pm	MEETING
2024 Annual Meeting of Shareholders	Wed, Aug 28 2024 11:00 am	MEETING
Strong first quarter supports profitable full year outlook	Thu, Aug 22 2024 08:30 am	MKTUPDTE
Notice of meeting and proxy form	Tue, Jul 30 2024 11:38 am	MEETING

Major Holdings Announcements

Date	Name	No. Held	%	Current
28/02/23	Roger Norman Macassey and Mark Andr	142,213,158	-	11.16
07/07/21	Probi Aktiebolag	166,148,034	-	13.04
18/05/20	Wen Yi	53,280,077	5.83	4.81
27/03/18	W. Wu	-	6.83	-
06/03/17	Edinburgh Equity Limited	31,157,388	5.59	2.81
08/02/17	Mingchun Qiu	39,000,000	5.50	3.52

Director’s Interests Announcements

Date	Name	No. Held	%	Details	Other
25/03/22	Brian David Watson	4,730,431	-	-	-
09/03/20	Anthony Paul Offen	31,157,388	-	-	-
06/03/20	Alison Stewart	350,000	-	-	-
11/04/19	Geoffrey Phil Plunket	800,000	-	-	-
05/04/19	Alison Barrass	200,000	-	-	-
03/08/18	Barry Charles Richardso 17,903,625	-	-		-
01/12/16	Timothy James Mepham	55,977	0.01	-	-

Analysts’ Forecasts

No forecasts available

Disclaimer

Data on this page is from BusinessDesk and NZX Ltd for information purposes only. Details are believed to be accurate but no warranty is given as to accuracy, timeliness, reliability or completeness. No person should rely on the contents of the report and all persons should obtain independent professional advice before acting on any information connected with or contained in this report.

Last Updated: 01/05/2023